Altria Group (formerly Philip Morris Companies) was spun off in 2003 to separate US tobacco from international operations (PM International). Altria is exclusively a US company with ~$20B annual revenue. It is best known for Marlboro — the world's best-selling cigarette brand, commanding ~43% US market share. After losing billions on JUUL and Cronos (cannabis), Altria pivoted to NJOY (e-vapor) and On! (nicotine pouches).

The math: Cigarette volumes decline ~10%/year but Altria raises prices ~5-6%/year. That's net revenue growth of -4-5% on volumes, partly offset by mix and price. This "harvest mode" generates enormous FCF — ~$7-8B annually — relative to its size. The strategic question is whether NJOY and On! can grow to offset cigarette decline long-term.

Key risks: (1) FDA menthol cigarette ban (delayed but not dead); (2) Illicit/disposable e-cig market stealing Marlboro users; (3) Excise tax increases; (4) NJOY not scaling fast enough before cigarette decline becomes structural problem.

Green = >10% above current price. Red = >10% below. Gold = within ±10%.

Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.

Bear case: Altria is in terminal decline. Volume declines of 10%+ per year cannot be offset by price increases forever — at some point the price elasticity breaks. NJOY is not gaining meaningful share in the e-vapor market dominated by illegal disposables from Chinese manufacturers. FDA menthol ban, if enacted, would be catastrophic — Marlboro menthol is ~$5B revenue. At $50 (analyst low), MO would still yield 8.5% but on a dividend that could face a cut within 3-5 years. The JUUL write-down was a $12.8B disaster. History suggests Altria's M&A judgment cannot be trusted.

Bull case: Marlboro is an irreplaceable cash cow. Despite volume declines, pricing power means the brand generates $10B+ in annual operating income year after year. On! nicotine pouches are the fastest-growing nicotine product in the US — Altria's product, gaining share from Zyn (PM). NJOY has FDA marketing authorization — unlike most e-cig brands. At 6.4% yield with 57 years of growth and $7B+ FCF, income investors will continue paying a premium. Bull target: $72-75 on multiple expansion.

Our view — Hold at current price, income play only: Our DDM base IV is $68.37 — slightly above current $66.51. Stock appears roughly fairly valued. Analyst consensus of $62.75 implies modest downside to consensus fair value. The 6.4% yield is attractive for income-focused investors, but we'd prefer a $60-62 entry for meaningful margin of safety. Joseph holds 4,479 shares at $50.01 avg cost — substantial profit. This is a harvest position; sell slowly on strength above $70.